BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FDA: Genzyme Corporation (GENZ), Isis Pharmaceuticals, Inc. (ISIS) Drug Mipomersen Cuts Cholesterol but Impacts Liver


10/16/2012 7:54:23 AM

Food and Drug Administration medical reviewers said mipomersen, a drug that would be marketed by Sanofi's (SNY, SNY.FR) Genzyme unit to treat a rare form of a disease that causes very high cholesterol was effective at reducing cholesterol, but raised concerns about the safety of the product.

Mipomersen, which has a proposed brand name of Kynamro, was developed by Isis Pharmaceuticals Inc. (ISIS). The companies are seeking FDA approval of the product to treat people with a condition called homozygous familial hypercholesterolemia, or HoFH, a disorder that causes very high cholesterol. The FDA estimates it affects one person out of one million people in the U.S. The companies are also developing the product for use in a different type of familial hypercholesterolemia, which affects more people, but that use is not the subject of FDA's current review.


Read at Fox News

Fox News
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES